Key result
Urinary 8-isoprostane shows no overall link to arterial stiffness but correlates with structural remodeling in subgroups.
Why the study?
Isoprostanes are oxidative stress biomarkers linked to arterial stiffness, but their cross-sectional and longitudinal associations with structural and load-dependent carotid stiffness had not been evaluated.
Are higher urinary 8-isoprostane and its metabolite concentrations associated with higher carotid T-PWV, S-PWV, and LD-PWV?
Are higher urinary 8-isoprostane and its metabolite concentrations associated with higher carotid T-PWV, S-PWV, and LD-PWV?
Single timepoint measures of urinary 8-isoprostane are not robust biomarkers for predicting arterial stiffness in the general population, though they may correlate with structural remodeling in specific subgroups.
Urinary 8-isoprostane should not guide arterial stiffness assessment in practice; leaves open hypothesis-generating associations with remodeling in White adults on angiotensin-II therapy.
Total carotid pulse wave velocity (T-PWV), a measure of arterial stiffness, is caused by structural (S) remodeling and elevated blood pressure exerting a pressure-load on the arterial wall. Isoprostanes are oxidative stress biomarkers that have been associated with arterial stiffness. We sought to investigate the cross-sectional and longitudinal associations of urinary 8-isoprostane (iPF2α-III) and its metabolite (iPF2α-III-M), measured at a single timepoint at baseline, with carotid T-PWV, S-PWV, and load-dependent (LD)-PWV in a subset (n=744) of participants enrolled in the Multi-Ethnic Study of Atherosclerosis. We hypothesized that higher iPF2α-III and iPF2α-III-M concentrations would be associated with higher T-PWV, S-PWV, and LD-PWV. These relationships were evaluated using multivariable linear regression models adjusted for potential confounders in the entire analytical sample and in analyses stratified by hypertension medication class and race/ethnicity. In cross-sectional analyses of the entire analytic sample, there were no associations of acute iPF2α-III or iPF2α-III-M with carotid T-PWV, S-PWV, or LD-PWV after adjusting for risk factors. In adults taking angiotensin-II acting anti-hypertensive medications, higher iPF2α-III was associated with higher S-PWV, while higher iPF2α-III-M was associated with higher T-PWV and S-PWV. In the entire analytic sample, baseline isoprostanes were not associated with carotid PWV measured nearly a decade later. However, in analyses stratified by race/ethnicity higher baseline iPF2α-III was associated with higher S-PWV nearly a decade later among self-identified White participants. These results suggest that single timepoint measures of urinary 8-isoprostane are not a robust biomarker of arterial stiffness but may be associated with structural remodeling in select populations.
No takes yet. Share an insight, caveat, or question.
DeConne et al. (2026) studied this question. Urinary 8-isoprostane levels are not robustly associated with arterial stiffness overall, but correlate with structural remodeling in White adults and those taking angiotensin-II medications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: